Johnson & Johnson (JNJ) operating KPIs
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026Score 12/3043% above fair value
$273.20−2.00 (-0.73%)
Close on Oct 30, 2026Market cap $658.38BP/E 31.7Yield 1.88%
Johnson & Johnson pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M)
Form 10-Q / 10-K Segment Note & Form 8-K EX-99.2 Segment Sales Schedule
Latest, Q3 2026
897
Period ended Sep 30, 2026
Change on a year earlier
-19.6%
1,115 in Q3 2025
History
39 quarters
Since Q1 2017
Sources
31
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
Breakdown
What makes up pulmonary hypertension (ph) therapeutic area total — worldwide sales ($m)
- Pulmonary Hypertension (PH) Therapeutic Area Total — U.S. sales ($M)588 · Q3 2026
- Pulmonary Hypertension (PH) Therapeutic Area Total — International sales ($M)309 · Q3 2026
- Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide reported growth YoY (%)-19.5% · Q3 2026
- Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide operational (constant-currency) growth YoY (%)-19.2% · Q3 2026
- UPTRAVI (selexipag) — Worldwide sales ($M)483 · Q3 2026
- OPSUMIT / OPSYNVI (macitentan) — Worldwide sales ($M)372 · Q3 2026
- TRACLEER (bosentan) [reported separately through FY2019Q4] — Worldwide sales ($M)56 · Q4 2019
- Other Pulmonary Hypertension medicines — Worldwide sales ($M)42 · Q3 2026
Cite this data
StockData. (2026). Johnson & Johnson Pulmonary Hypertension (PH) Therapeutic Area Total — Worldwide sales ($M) ($M), quarterly Q1 2017–Q3 2026 [Data set]. Compiled from Johnson & Johnson SEC filings and investor materials. https://stockdatahq.com/stocks/jnj/kpis/ta_pulm_hypertension
See every metric in the Johnson & Johnson KPI table. Data updated Oct 25, 2026.